Maria Novella Romanelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5117294/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2-(2-Hydroxyethyl)piperazine derivatives as potent human carbonic anhydrase inhibitors: Synthesis, enzyme inhibition, computational studies and antiglaucoma activity. European Journal of Medicinal Chemistry, 2022, 228, 114026.	2.6	1
2	New Histamine-Related Five-Membered N-Heterocycle Derivatives as Carbonic Anhydrase I Activators. Molecules, 2022, 27, 545.	1.7	2
3	Overcoming Multidrug Resistance (MDR): Design, Biological Evaluation and Molecular Modelling Studies of 2,4â€Substituted Quinazoline Derivatives. ChemMedChem, 2022, 17, .	1.6	6
4	Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury. Neurotherapeutics, 2022, 19, 1634-1648.	2.1	9
5	Dual HDAC–BRD4 inhibitors endowed with antitumor and antihyperalgesic activity. Medicinal Chemistry Research, 2022, 31, 960-974.	1.1	2
6	The piperazine scaffold for novel drug discovery efforts: the evidence to date. Expert Opinion on Drug Discovery, 2022, 17, 969-984.	2.5	9
7	The HCN channel as a pharmacological target: Why, where, and how to block it. Progress in Biophysics and Molecular Biology, 2021, 166, 173-181.	1.4	11
8	Carbonic Anhydrase IV Selective Inhibitors Counteract the Development of Colitis-Associated Visceral Pain in Rats. Cells, 2021, 10, 2540.	1.8	3
9	Dual BET/HDAC inhibition to relieve neuropathic pain: Recent advances, perspectives, and future opportunities. Pharmacological Research, 2021, 173, 105901.	3.1	13
10	Type I and type II positive allosteric modulators of α7 nicotinic acetylcholine receptors induce antidepressant-like activity in mice by a mechanism involving receptor potentiation but not neurotransmitter reuptake inhibition. Correlation with mTOR intracellular pathway activation.	0.3	7
11	Evaluating the efficiency of enzyme accelerated CO2 capture: chemical kinetics modelling for interpreting measurement results. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 394-401.	2.5	2
12	A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 391-397.	2.5	19
13	(<i>E</i>)-3-Furan-2-yl- <i>N</i> - <i>p</i> -tolyl-acrylamide and its Derivative DM489 Decrease Neuropathic Pain in Mice Predominantly by î±7 Nicotinic Acetylcholine Receptor Potentiation. ACS Chemical Neuroscience, 2020, 11, 3603-3614.	1.7	16
14	A measurement system for the evaluation of efficiency of enzyme accelerated CO2 capture systems based on modeling. , 2020, , .		1
15	Synthesis and carbonic anhydrase activating properties of a series of 2-amino-imidazolines structurally related to clonidine ¹ . Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1003-1010.	2.5	6
16	Carbachol dimers with primary carbamate groups as homobivalent modulators of muscarinic receptors. European Journal of Pharmacology, 2020, 883, 173183.	1.7	6
17	6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline amides and corresponding ester isosteres as multidrug resistance reversers. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 974-992.	2.5	12
18	Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells. Molecules, 2020, 25, 1748.	1.7	30

#	Article	IF	CITATIONS
19	Sulfonamides incorporating piperazine bioisosteres as potent human carbonic anhydrase I, II, IV and IX inhibitors. Bioorganic Chemistry, 2019, 91, 103130.	2.0	12
20	Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers. European Journal of Medicinal Chemistry, 2019, 182, 111655.	2.6	21
21	New Rigid Nicotine Analogues, Carrying a Norbornane Moiety, Are Potent Agonists of α7 and α3* Nicotinic Receptors. Journal of Medicinal Chemistry, 2019, 62, 1887-1901.	2.9	6
22	The Hyperpolarization-Activated HCN4 Channel is Important for Proper Maintenance of Oscillatory Activity in the Thalamocortical System. Cerebral Cortex, 2019, 29, 2291-2304.	1.6	49
23	Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators. European Journal of Medicinal Chemistry, 2019, 172, 71-94.	2.6	27
24	EC18 as a Tool To Understand the Role of HCN4 Channels in Mediating Hyperpolarization-Activated Current in Tissues. ACS Medicinal Chemistry Letters, 2019, 10, 584-589.	1.3	12
25	Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators. , 2019, 2, 710-743.		9
26	2-Benzylpiperazine: A new scaffold for potent human carbonic anhydrase inhibitors. Synthesis, enzyme inhibition, enantioselectivity, computational and crystallographic studies and inÂvivo activity for a new class of intraocular pressure lowering agents. European Journal of Medicinal Chemistry, 2018, 151, 363-375.	2.6	29
27	Design and synthesis of new potent N,N -bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents. European Journal of Medicinal Chemistry, 2018, 147, 7-20.	2.6	13
28	Investigation of piperazines as human carbonic anhydrase I, II, IV and VII activators. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 303-308.	2.5	7
29	Designing selective modulators for the nicotinic receptor subtypes: challenges and opportunities. Future Medicinal Chemistry, 2018, 10, 433-460.	1.1	10
30	Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR). Bioorganic and Medicinal Chemistry, 2018, 26, 50-64.	1.4	15
31	Selective Blockade of HCN1/HCN2 Channels as a Potential Pharmacological Strategy Against Pain. Frontiers in Pharmacology, 2018, 9, 1252.	1.6	40
32	Hyperpolarization-activated cyclic-nucleotide-gated channels: pathophysiological, developmental, and pharmacological insights into their function in cellular excitability. Canadian Journal of Physiology and Pharmacology, 2018, 96, 977-984.	0.7	20
33	Amino Acids as Building Blocks for Carbonic Anhydrase Inhibitors. Metabolites, 2018, 8, 36.	1.3	22
34	Piperazines as nootropic agents: New derivatives of the potent cognition-enhancer DM235 carrying hydrophilic substituents. Bioorganic and Medicinal Chemistry, 2017, 25, 1795-1803.	1.4	7
35	Structure–Activity Relationship Studies on 6,7â€Dimethoxyâ€2â€phenethylâ€1,2,3,4â€ŧetrahydroisoquinoline Derivatives as Multidrug Resistance Reversers. ChemMedChem, 2017, 12, 1369-1379.	1.6	19
36	The new HDAC1 inhibitor LG325 ameliorates neuropathic pain in a mouse model. Pharmacology Biochemistry and Behavior, 2017, 160, 70-75.	1.3	35

#	Article	IF	CITATIONS
37	The Hyperpolarization-Activated Cyclic Nucleotide–Gated Channels: from Biophysics to Pharmacology of a Unique Family of Ion Channels. Pharmacological Reviews, 2017, 69, 354-395.	7.1	103
38	Significance of the nicotinic alpha7 receptor in cognition and antipsychotic-like behavior in the rat. Behavioural Brain Research, 2017, 333, 129-134.	1.2	12
39	N -alkanol- N -cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy. European Journal of Medicinal Chemistry, 2017, 127, 586-598.	2.6	10
40	HCN Channels Modulators: The Need for Selectivity. Current Topics in Medicinal Chemistry, 2016, 16, 1764-1791.	1.0	54
41	Two types of interneurons in the mouse lateral geniculate nucleus are characterized by different h-current density. Scientific Reports, 2016, 6, 24904.	1.6	35
42	Carbachol dimers as homobivalent modulators of muscarinic receptors. Biochemical Pharmacology, 2016, 108, 90-101.	2.0	8
43	New quinoline derivatives as nicotinic receptor modulators. European Journal of Medicinal Chemistry, 2016, 110, 246-258.	2.6	4
44	Arylamino Esters As Pâ€Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity. ChemMedChem, 2015, 10, 1339-1343.	1.6	11
45	Substituted piperazines as nootropic agents: 2- or 3-phenyl derivatives structurally related to the cognition-enhancer DM235. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1700-1704.	1.0	14
46	<scp>HDAC</scp> â€inhibitor (S)â€8 disrupts <scp>HDAC</scp> 6â€ <scp>PP</scp> 1 complex prompting A375 melanoma cell growth arrest and apoptosis. Journal of Cellular and Molecular Medicine, 2015, 19, 143-154.	1.6	25
47	Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology. Current Drug Targets, 2015, 16, 868-876.	1.0	23
48	Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters. European Journal of Medicinal Chemistry, 2014, 87, 398-412.	2.6	20
49	New structure–activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR). Bioorganic and Medicinal Chemistry, 2013, 21, 456-465.	1.4	17
50	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring. European Journal of Medicinal Chemistry, 2013, 66, 56-68.	2.6	16
51	Effectiveness of the Histone Deacetylase Inhibitor (S)-2 against LNCaP and PC3 Human Prostate Cancer Cells. PLoS ONE, 2013, 8, e58267.	1.1	24
52	Novel blockers of hyperpolarizationâ€activated current with isoform selectivity in recombinant cells and native tissue. British Journal of Pharmacology, 2012, 166, 602-616.	2.7	44
53	Influence of ring size on the cognition-enhancing activity of DM235 and MN19, two potent nootropic drugs. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1936-1939.	1.0	7
54	Synthesis and Biological Evaluation of 3,7-Diazabicyclo[4.3.0]nonan-8-ones as Potential Nootropic and Analgesic Drugs. Journal of Medicinal Chemistry, 2011, 54, 2512-2516.	2.9	7

#	Article	IF	CITATIONS
55	Inhibition of P-glycoprotein-mediated Multidrug Resistance (MDR) by N,N-bis(cyclohexanol)amine aryl esters: Further restriction of molecular flexibility maintains high potency and efficacy. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 106-109.	1.0	14
56	Structureâ^'Activity Relationships Studies in a Series of N,N-Bis(alkanol)amine Aryl Esters as P-Glycoprotein (Pgp) Dependent Multidrug Resistance (MDR) Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 1755-1762.	2.9	25
57	Design, Synthesis, and Preliminary Biological Evaluation of New Isoform-Selective f-Current Blockers. Journal of Medicinal Chemistry, 2010, 53, 6773-6777.	2.9	35
58	Synthesis, Affinity Profile and Functional Activity of Potent Chiral Muscarinic Antagonists with a Pyrrolidinylfuran Structure. Journal of Medicinal Chemistry, 2010, 53, 201-207.	2.9	4
59	Design, synthesis and nootropic activity of new analogues of sunifiram and sapunifiram, two potent cognition-enhancers. Bioorganic and Medicinal Chemistry, 2009, 17, 7606-7614.	1.4	9
60	<i>N</i> , <i>N</i> -bis(Cyclohexanol)amine Aryl Esters: A New Class of Highly Potent Transporter-Dependent Multidrug Resistance Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 807-817.	2.9	30
61	Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers. Bioorganic and Medicinal Chemistry, 2008, 16, 1431-1443.	1.4	13
62	Docking analyses on human muscarinic receptors: Unveiling the subtypes peculiarities in agonists binding. Bioorganic and Medicinal Chemistry, 2008, 16, 3049-3058.	1.4	7
63	Muscarinic antagonists with multiple stereocenters: Synthesis, affinity profile and functional activity of isomeric 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine sulfoxide derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 5490-5500.	1.4	6
64	Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators. Bioorganic and Medicinal Chemistry, 2008, 16, 10034-10042.	1.4	11
65	Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5071-5074.	1.0	27
66	Synthesis and Pharmacological Characterization of Chiral Pyrrolidinylfuran Derivatives: The Discovery of New Functionally Selective Muscarinic Agonists. Journal of Medicinal Chemistry, 2008, 51, 3905-3912.	2.9	6
67	The quest for the treatment of cognitive impairment: α ₇ nicotinic and α ₅ GABA _A receptor modulators. Expert Opinion on Therapeutic Patents, 2007, 17, 1365-1377.	2.4	7
68	Design, Synthesis, and Preliminary Pharmacological Evaluation of New Quinoline Derivatives as Nicotinic Ligands. Journal of Medicinal Chemistry, 2007, 50, 4993-5002.	2.9	11
69	Synthesis, Affinity Profile, and Functional Activity of Muscarinic Antagonists with a 1-Methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine Structure. Journal of Medicinal Chemistry, 2007, 50, 1409-1413.	2.9	13
70	lsomeric N,N-Bis(cyclohexanol)amine Aryl Esters:  The Discovery of a New Class of Highly Potent P-Glycoprotein (Pgp)-dependent Multidrug Resistance (MDR) Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 599-602.	2.9	16
71	Central Nicotinic Receptors: Structure, Function, Ligands, and Therapeutic Potential. ChemMedChem, 2007, 2, 746-767.	1.6	168
72	Highly Chiral Muscarinic Ligands:  The Discovery of (2S,2â€~R,3â€~S,5â€~R)-1-Methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine 3-sulfoxide Methyl Iodide, a Potent, Functionally Selective, M2 Partial Agonist. Journal of Medicinal Chemistry, 2006, 49, 1925-1931.	2.9	21

#	Article	IF	CITATIONS
73	Pharmacological Characterization of DM232 (Unifiram) and DM235 (Sunifiram), New Potent Cognition Enhancers. CNS Neuroscience & Therapeutics, 2006, 12, 39-52.	4.0	15
74	Design of novel nicotinic ligands through 3D database searching. Bioorganic and Medicinal Chemistry, 2005, 13, 799-807.	1.4	14
75	Design, synthesis and preliminary biological evaluation of zatebradine analogues as potential blockers of the hyperpolarization-activated current. Bioorganic and Medicinal Chemistry, 2005, 13, 1211-1220.	1.4	22
76	Muscarinic subtype affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine derivatives. Biochemical Pharmacology, 2005, 69, 1637-1645.	2.0	24
77	Rigid analogs of DMPP as probes for the nicotinic receptors. Il Farmaco, 2005, 60, 99-104.	0.9	0
78	Design, Synthesis, and Preliminary Pharmacological Evaluation of a Set of Small Molecules That Directly Activate Gi Proteins. Journal of Medicinal Chemistry, 2005, 48, 6491-6503.	2.9	7
79	Exploratory Chemistry toward the Identification of a New Class of Multidrug Resistance Reverters Inspired by Pervilleine and Verapamil Models. Journal of Medicinal Chemistry, 2005, 48, 7426-7436.	2.9	39
80	Enantioselective Synthesis and Preliminary Pharmacological Evaluation of the Enantiomers of Unifiram (DM232), a Potent Cognition-Enhancing Agent. Medicinal Chemistry, 2005, 1, 473-480.	0.7	7
81	Structure–activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs. Bioorganic and Medicinal Chemistry, 2004, 12, 71-85.	1.4	19
82	Design, Synthesis, and Preliminary Pharmacological Evaluation of 4-Aminopiperidine Derivatives as N-Type Calcium Channel Blockers Active on Pain and Neuropathic Pain. Journal of Medicinal Chemistry, 2004, 47, 6070-6081.	2.9	27
83	Cholinergic nicotinic receptors: Competitive ligands, allosteric modulators, and their potential applications. Medicinal Research Reviews, 2003, 23, 393-426.	5.0	107
84	4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2303-2306.	1.0	18
85	Synthesis and cholinergic affinity of diastereomeric and enantiomeric isomers of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)- pyrrolidine, 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine and of Their iodomethylates. Bioorganic and Medicinal Chemistry, 2003, 11, 3153-3164.	1.4	16
86	Design and Study of Piracetam-like Nootropics, Controversial Members of the Problematic Class of Cognition-Enhancing Drugs. Current Pharmaceutical Design, 2002, 8, 125-138.	0.9	102
87	Synthesis and pharmacological evaluation of some (pyridyl)cyclopropylmethyl amines and their methiodides as nicotinic receptor ligands. Il Farmaco, 2002, 57, 487-496.	0.9	3
88	Sigma Receptor Binding Profile of a Series of Analgesic Tropane Derivatives. Archiv Der Pharmazie, 2002, 335, 39-43.	2.1	3
89	Structureâ^'Affinity Relationships of a Unique Nicotinic Ligand:Â N1-Dimethyl-N4-phenylpiperazinium Iodide (DMPP). Journal of Medicinal Chemistry, 2001, 44, 3946-3955.	2.9	42
90	Molecular Simplification of 1,4-Diazabicyclo[4.3.0]nonan-9-ones Gives Piperazine Derivatives That Maintain High Nootropic Activity. Journal of Medicinal Chemistry, 2000, 43, 4499-4507.	2.9	30

#	Article	IF	CITATIONS
91	Design, Synthesis, and Preliminary Pharmacological Evaluation of 1,4-Diazabicyclo[4.3.0]nonan-9-ones as a New Class of Highly Potent Nootropic Agents. Journal of Medicinal Chemistry, 2000, 43, 1969-1974.	2.9	30
92	Hybridized and isosteric analogues of N 1 -acetyl- N 4 -dimethyl-piperazinium iodide (ADMP) and N 1 -phenyl- N 4 -dimethyl-piperazinium iodide (DMPP) with central nicotinic action. Bioorganic and Medicinal Chemistry, 1999, 7, 457-465.	1.4	26
93	Synthesis and binding properties of photoactivable biotin-conjugated verapamil derivatives for the study of P-170 glycoprotein. Bioorganic and Medicinal Chemistry, 1999, 7, 1873-1880.	1.4	6
94	Design, Synthesis, and in Vitro Activity of Catamphiphilic Reverters of Multidrug Resistance:Â Discovery of a Selective, Highly Efficacious Chemosensitizer with Potency in the Nanomolar Range. Journal of Medicinal Chemistry, 1999, 42, 1687-1697.	2.9	51
95	ANTINOCICEPTION INDUCED BY SM 32 DEPENDS ON A CENTRAL CHOLINERGIC MECHANISM. Pharmacological Research, 1997, 35, 141-147.	3.1	4
96	Chiral synthesis and pharmacological evaluation of the enantiomers of SM32, a new analgesic and cognition-enhancing agent. , 1996, 8, 579-584.		5
97	Reduced Flexibility Analogs of Analgesic and Cognition Enhancing α-Tropanyl Esters. Archiv Der Pharmazie, 1996, 329, 105-111.	2.1	5
98	Analgesic effects of myrrh. Nature, 1996, 379, 29-29.	13.7	105
99	Semi-rigid analogues of the calcium antagonist verapamil: A molecular modelling study. Journal of Computer-Aided Molecular Design, 1994, 8, 123-134.	1.3	7
100	Presynaptic Cholinergic Modulators as Potent Cognition Enhancers and Analgesic Drugs. 2. 2-Phenoxy-, 2-(Phenylthio)-, and 2-(Phenylamino)alkanoic Acid Esters. Journal of Medicinal Chemistry, 1994, 37, 1712-1719.	2.9	33
101	Presynaptic Cholinergic Modulators as Potent Cognition Enhancers and Analgesic Drugs. 1. Tropic and 2-Phenylpropionic Acid Esters. Journal of Medicinal Chemistry, 1994, 37, 1704-1711.	2.9	32